CIP
RETA

Chartwell Investment Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Chartwell Investment Partners’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,925
Closed -$768K – 436
2020
Q2 		$768K Buy
+4,925
New +$749K 0.03% 352

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Chartwell Investment Partners's RETA Position: Q3 2020 in Review

Chartwell Investment Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 4,925 shares — an estimated $768K sold.

Chartwell Investment Partners first reported a position in RETA in Q2 2020 and held it in 1 quarter. The position peaked at $768K in Q2 2020. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

  • Chartwell Investment Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
  • Chartwell Investment Partners sold 4,925 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $768K.
  • Chartwell Investment Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 1 quarter.
  • Chartwell Investment Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $768K in Q2 2020.
  • 186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Chartwell Investment Partners's 13F filing for Q3 2020, filed 16 Nov 2020.